BENDER REINHOLD R. W
No ORCID on file
· 34 papers in corpus
· active 2002-2004
Frequent coauthors
- ZHANG PUWEN 34
- EDWARDS JAMES P 34
- GRUBB GARY S 34
- JONES TODD K 34
- TEGLEY CHRISTOPHER M 34
- WROBEL JAY E 34
- ZHI LIN 34
- BENDER REINHOLD R.W 17
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2004
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:A is O, S, or NR; B is a bond or CRR;R, to Rare H, C1 to C6…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…
2002
This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure: A is O, S, or NR4; B is a bond or CR5R6; R4, to R6 are…